NOV (NOV)
(Real Time Quote from BATS)
$18.68 USD
+0.43 (2.36%)
Updated Jul 25, 2024 02:47 PM ET
4-Sell of 5 4
A Value F Growth C Momentum C VGM
Price, Consensus and EPS Surprise
NOV 18.68 +0.43(2.36%)
Will NOV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NOV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NOV
Factors You Need to Know Ahead of NOV Q2 Earnings Release
Climb Global (CLMB) Moves 8.5% Higher: Will This Strength Last?
NOV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is NOV (NOV) Stock Undervalued Right Now?
Nov Inc. (NOV) is a Top-Ranked Value Stock: Should You Buy?
Nov Inc. (NOV) is a Top-Ranked Value Stock: Should You Buy?
Other News for NOV
Novatti Divests Banking Interest to Refocus Strategy
Novatti Group Requests Immediate Trading Halt
Notable Two Hundred Day Moving Average Cross - NOV
Goldman Sachs Keeps Their Buy Rating on Novo Nordisk (0QIU)
Novatti Group Lists New Options on ASX